Meet the UAMS Entrepreneurs Selected for 2025 Accelerator Cohort: John Arthur, M.D., Ph.D., Nephrology; Marie Burdine, Ph.D., Biochemistry and Molecular Biology; Zachary Waldrip, Ph.D., Surgical Research.
The deadline has been extended for UAMS employees to submit innovative therapeutic or drug discovery ideas to the AR Health Ventures Accelerator (ARHVA) for significant financial and administrative support toward commercialization. Selected projects receive financial grants of up to $50,000 project management, budget allocation and progress tracking. All UAMS employees are eligible to apply, including trainees and postdoctoral fellows. The full Request for Applications document outlining the application process is available on the BioVentures website, as is a detailed FAQ. Applications are due Oct. 31. For more information, contact BioVentures Senior Program Manager Stefanie Kennon-McGill, Ph.D., at skennonmcgill@uams.edu.
The AR Health Ventures Accelerator (ARHVA) invites UAMS employees to submit innovative therapeutic or drug discovery ideas for significant financial and administrative support toward commercialization. Selected projects receive financial grants of up to $50,000, project management, budget allocation and progress tracking. This unique support framework allows researchers to focus on their innovations, while ARHVA ensures projects stay on track, increasing the commercial value and paving the way for successful licensing, partnerships or startups. All UAMS employees are eligible to apply, including trainees and postdoctoral fellows. The full Request for Applications document outlining the application process is available on the ARHVA website, as is a detailed FAQ. The application period begins August 26, 2024, and runs through September 30, 2024, at 5 PM. The funding decision announcement will be November 29, 2024. Read about inaugural ARHVA cohort, who are tackling biofilm formation in Staphylococcus aureus infections, radiation-responsive liposomes for cancer therapy, and a novel biomarker for liver injury detection. For more information, contact BioVentures Senior Program Manager Stefanie Kennon-McGill, Ph.D., at skennonmcgill@uams.edu.
AR Health Ventures Accelerator proudly announces its inaugural cohort, funding innovative projects in biofilm inhibition, radiation-responsive cancer therapy, and advanced liver injury detection, marking a significant leap in medical research.
Submit your proposals for the AR Health Ventures Accelerator program by September 29th. Apply now!
